CALITHERA BIOSCIENCES INC (CALA)

US13089P5070 - Common Stock

0.3651  -0.04 (-10.95%)

After market: 0.3401 -0.02 (-6.85%)

News Image
10 months ago - Calithera Biosciences, Inc.

Calithera Biosciences Announces Update on Complete Liquidation and Dissolution

Cancels Special Meeting of Stockholders...

News Image
a year ago - Calithera Biosciences, Inc.

Calithera Biosciences Announces Update on Complete Liquidation and Dissolution

Special Meeting to be Held on or about June 29, 2023 with a Record Date of May 25, 2023...

News Image
a year ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

It's time to start off the day with an overview of the biggest pre-market stock movers traders need to know about on Wednesday!

News Image
a year ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

We're starting off the day with an overview of the biggest pre-market stock movers traders need to know about for Tuesday!

News Image
a year ago - Calithera Biosciences, Inc.

Calithera Biosciences Announces Board Approval of Complete Liquidation and Dissolution

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), today announced that its Board of Directors...

News Image
a year ago - Calithera Biosciences, Inc.

Calithera Biosciences Reports Third Quarter 2022 Financial Results and Business Update

-- Conference Call and Webcast Scheduled for 5:00 p.m. ET on Monday, November 14, 2022 --...

News Image
a year ago - Calithera Biosciences, Inc.

Calithera Biosciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology...

News Image
2 years ago - Calithera Biosciences, Inc.

Calithera Receives FDA Fast Track Designation for Sapanisertib for the Treatment of NRF2-mutated Squamous Lung Cancer

Enrollment ongoing in Phase 2 study evaluating sapanisertib, a dual mTORC1/2 inhibitor, in patients with squamous non-small cell lung cancer harboring a...

News Image
2 years ago - InvestorPlace

3 Penny Stocks With Surprisingly Superior Fundamentals

You probably haven't heard of any of these penny stocks, but their fundamentals make them worth a look for investors with speculative capital.

News Image
2 years ago - Calithera Biosciences, Inc.

Calithera to Present at the H.C. Wainwright 24th Annual Global Investment Conference

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology...

News Image
2 years ago - Calithera Biosciences, Inc.

Calithera Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights

-- Conference Call and Webcast Scheduled for 5:00 p.m. ET on Monday, August 15, 2022 --...